Gamma to acquire majority stake in Mirus Bio

By The Science Advisory Board staff writers

May 18, 2021 -- Gamma Biosciences has purchased a controlling stake in Mirus Bio, a developer of lipid-polymer nanocomplexes for nucleic acid delivery.

The deal expands Gamma Biosciences' reach in gene therapy and next-generation vaccines, while supporting the launch of Mirus Bio's flagship TransIT VirusGen platform for manufacturing of adeno-associated viruses (AAV) and lentivirus-based viral vectors for gene therapy. The investment will also help to further develop and commercialize TransIT VirusGen for in vivo delivery applications, according to the companies.

Terms of the agreement were not disclosed.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.